Tepilukimig

Tepilukimig is a bivalent humanized IgG1κ monoclonal antibody inhibitor targeting TSLP-IL7Rα and TSLP-CRLF2. Tepilukimig inhibits the binding of TSLP to its receptors (IL7Rα and CRLF2) on the cell surface, thereby completely interrupting the inflammatory signaling pathway driven by TSLP. Tepilukimig can be used for allergic and inflammatory diseases like atopic dermatitis and asthma research[1][2].

Product Specifications

CAS Number

[2985643-31-8]

UNSPSC

12352100

Target

Interleukin Related

Related Pathways

Immunology/Inflammation

Field of Research

Inflammation/Immunology

References & Citations

[1]Smolinska S, et al. Thymic Stromal Lymphopoietin (TSLP), Its Isoforms and the Interplay with the Epithelium in Allergy and Asthma. Int J Mol Sci. 2023 Aug 12;24 (16) :12725.|[2]Internacionales D C. International Nonproprietary Names for Pharmaceutical Substances (INN) [J]. WHO Drug Information, 2025, 39 (2) .